Inceptionr LLC Buys Shares of 5,172 Insmed, Inc. $INSM

Inceptionr LLC purchased a new position in Insmed, Inc. (NASDAQ:INSM) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 5,172 shares of the biopharmaceutical company’s stock, valued at approximately $846,000.

A number of other hedge funds have also recently modified their holdings of the business. CIBC Private Wealth Group LLC increased its stake in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares in the last quarter. CoreCap Advisors LLC purchased a new position in Insmed during the fourth quarter valued at $27,000. GraniteShares Advisors LLC purchased a new position in Insmed during the fourth quarter valued at $30,000. Reflection Asset Management purchased a new position in Insmed during the fourth quarter valued at $30,000. Finally, Raiffeisen Bank International AG bought a new stake in Insmed during the fourth quarter valued at about $32,000.

Insmed Stock Performance

NASDAQ:INSM opened at $106.92 on Friday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75. The stock has a 50-day moving average price of $105.20 and a 200 day moving average price of $133.54. The stock has a market capitalization of $23.17 billion, a P/E ratio of -18.59 and a beta of 0.78.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. During the same quarter last year, the company earned ($1.42) EPS. The firm’s quarterly revenue was up 229.7% on a year-over-year basis. Equities research analysts forecast that Insmed, Inc. will post -2.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on INSM. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research report on Friday, July 17th. Royal Bank Of Canada lowered their price objective on Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Mizuho set a $192.00 price objective on Insmed in a research note on Tuesday, June 16th. Morgan Stanley raised shares of Insmed from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $166.00 to $212.00 in a report on Monday, March 30th. Finally, Barclays raised their target price on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Insmed has an average rating of “Buy” and an average target price of $209.13.

Insider Activity at Insmed

In other news, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $117.40, for a total value of $1,256,062.60. Following the transaction, the chief executive officer owned 259,058 shares of the company’s stock, valued at approximately $30,413,409.20. The trade was a 3.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 1,806 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total transaction of $173,050.92. Following the transaction, the insider owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 54,590 shares of company stock valued at $5,793,738. Corporate insiders own 2.10% of the company’s stock.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.